Royal London Asset Management’s Quest Diagnostics DGX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $10.1M | Buy |
51,570
+7,193
| +16% | +$1.4M | 0.02% | 452 |
|
|
2025
Q4 | $7.7M | Buy |
44,377
+342
| +0.8% | +$62.3K | 0.02% | 488 |
|
|
2025
Q3 | $8.39M | Sell |
44,035
-3,842
| -8% | -$682K | 0.02% | 477 |
|
|
2025
Q2 | $8.6M | Sell |
47,877
-916
| -2% | -$159K | 0.02% | 465 |
|
|
2025
Q1 | $8.26M | Sell |
48,793
-3,971
| -8% | -$652K | 0.02% | 472 |
|
|
2024
Q4 | $7.96M | Sell |
52,764
-913
| -2% | -$142K | 0.02% | 459 |
|
|
2024
Q3 | $8.33M | Buy |
53,677
+1,339
| +3% | +$200K | 0.02% | 457 |
|
|
2024
Q2 | $7.16M | Sell |
52,338
-2,000
| -4% | -$274K | 0.02% | 459 |
|
|
2024
Q1 | $7.23M | Hold |
54,338
| – | – | 0.02% | 475 |
|
|
2023
Q4 | $7.49M | Buy |
54,338
+10,104
| +23% | +$1.33M | 0.02% | 449 |
|
|
2023
Q3 | $5.39M | Buy |
44,234
+998
| +2% | +$133K | 0.02% | 489 |
|
|
2023
Q2 | $6.08M | Buy |
43,236
+4,150
| +11% | +$572K | 0.02% | 463 |
|
|
2023
Q1 | $5.53M | Sell |
39,086
-1,043
| -3% | -$149K | 0.02% | 446 |
|
|
2022
Q4 | $6.28M | Hold |
40,129
| – | – | 0.03% | 409 |
|
|
2022
Q3 | $4.93M | Sell |
40,129
-2,723
| -6% | -$359K | 0.03% | 432 |
|
|
2022
Q2 | $5.7M | Hold |
42,852
| – | – | 0.03% | 411 |
|
|
2022
Q1 | $5.87M | Buy |
42,852
+2,897
| +7% | +$404K | 0.02% | 458 |
|
|
2021
Q4 | $6.92M | Sell |
39,955
-9,741
| -20% | -$1.48M | 0.03% | 424 |
|
|
2021
Q3 | $7.22M | Hold |
49,696
| – | – | 0.03% | 404 |
|
|
2021
Q2 | $6.56M | Hold |
49,696
| – | – | 0.03% | 439 |
|
|
2021
Q1 | $6.38M | Buy |
49,696
+1,460
| +3% | +$180K | 0.03% | 417 |
|
|
2020
Q4 | $5.75M | Sell |
48,236
-4,911
| -9% | -$599K | 0.03% | 404 |
|
|
2020
Q3 | $6.04M | Hold |
53,147
| – | – | 0.04% | 351 |
|
|
2020
Q2 | $5.87M | Sell |
53,147
-2,298
| -4% | -$244K | 0.04% | 350 |
|
|
2020
Q1 | $4.61M | Sell |
55,445
-2,618
| -5% | -$271K | 0.04% | 387 |
|
|
2019
Q4 | $6.17M | Buy |
58,063
+6,663
| +13% | +$695K | 0.04% | 363 |
|
|
2019
Q3 | $5.5M | Buy |
51,400
+1,446
| +3% | +$148K | 0.04% | 386 |
|
|
2019
Q2 | $5.08M | Sell |
49,954
-1,436
| -3% | -$138K | 0.05% | 347 |
|
|
2019
Q1 | $4.62M | Sell |
51,390
-9,942
| -16% | -$862K | 0.04% | 446 |
|
|
2018
Q4 | $5.03M | Buy |
61,332
+5,037
| +9% | +$472K | 0.04% | 402 |
|
|
2018
Q3 | $6.08M | Sell |
56,295
-2,455
| -4% | -$269K | 0.06% | 300 |
|
|
2018
Q2 | $6.46M | Buy |
+58,750
| New | +$6.12M | 0.07% | 312 |
|
|
2016
Q2 | $4.21M | Sell |
51,735
-2,472,703
| -98% | -$188M | 0.07% | 296 |
|
|
2016
Q1 | $35K | Buy |
2,524,438
+2,472,285
| +4,740% | +$166M | 0.05% | 377 |
|
|
2015
Q4 | $3.74M | Buy |
52,153
+2,515
| +5% | +$169K | 0.06% | 346 |
|
|
2015
Q3 | $3.05M | Buy |
+49,638
| New | +$3.47M | 0.05% | 395 |
|
|
2014
Q4 | $32.4K | Buy |
47,667
+12,587
| +36% | +$794K | 0.06% | 334 |
|
|
2014
Q3 | $2.16M | Buy |
35,080
+1,365
| +4% | +$84.1K | 0.05% | 363 |
|
|
2014
Q2 | $2.04M | Sell |
33,715
-152
| -0.4% | -$8.9K | 0.05% | 406 |
|
|
2014
Q1 | $1.94M | Sell |
33,867
-1,800
| -5% | -$96.5K | 0.05% | 422 |
|
|
2013
Q4 | $1.92M | Sell |
35,667
-240
| -0.7% | -$14.2K | 0.05% | 408 |
|
|
2013
Q3 | $2.09M | Buy |
35,907
+633
| +2% | +$37.9K | 0.06% | 376 |
|
|
2013
Q2 | $2.17M | Buy |
+35,274
| New | +$2.1M | 0.06% | 342 |
|
Other funds holding DGX
VCM
VPM
EIG
Royal London Asset Management's DGX Position: Q1 2026 in Review
Royal London Asset Management increased its Quest Diagnostics (DGX) stake by 16% in Q1 2026, buying an estimated $1.4M and bringing the position to 51,570 shares worth $10.1M. The position accounts for 0.02% of the portfolio, ranked #452.
Royal London Asset Management first reported a position in DGX in Q2 2013 and has held it in 43 quarters since. 1,066 funds tracked by Wall St. Rank hold DGX as of Q1 2026.
- Royal London Asset Management held 51,570 shares of Quest Diagnostics worth $10.1M as of Q1 2026.
- Royal London Asset Management bought 7,193 Quest Diagnostics shares in Q1 2026, an estimated $1.4M.
- Quest Diagnostics made up 0.02% of Royal London Asset Management's portfolio in Q1 2026, its #452 holding.
- Royal London Asset Management first reported a position in Quest Diagnostics in Q2 2013 and has held it in 43 quarters since.
- 1,066 funds tracked by Wall St. Rank held Quest Diagnostics as of Q1 2026.
Based on Royal London Asset Management's 13F filing for Q1 2026, filed 1 May 2026.